AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
doxercalciferol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| Vitamin D analogues/derivatives | 957 | 54573-75-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
decrease of bone density caused by prednisolone was prevented by above cpd; decreases number of osteoclast areas in normal rats; RN given refers to (1alpha,3beta,5Z,7E,22E)-isomer
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 14 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 9, 1999 | FDA | GENZYME CORP |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 367.52 | 42.44 | 136 | 604 | 463473 | 90164234 |
| Pruritus | 62.60 | 42.44 | 44 | 696 | 541481 | 90086226 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 281.03 | 46.66 | 89 | 562 | 99300 | 42521384 |
| Pruritus | 56.07 | 46.66 | 35 | 616 | 188736 | 42431948 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 620.76 | 46.26 | 224 | 1173 | 453866 | 110134036 |
| Pruritus | 108.27 | 46.26 | 75 | 1322 | 581485 | 110006417 |
| Dyspnoea | 68.06 | 46.26 | 76 | 1321 | 1106796 | 109481106 |
| Flushing | 59.04 | 46.26 | 28 | 1369 | 104708 | 110483194 |
| Unresponsive to stimuli | 51.72 | 46.26 | 22 | 1375 | 63768 | 110524134 |
| Feeling hot | 47.21 | 46.26 | 23 | 1374 | 91083 | 110496819 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H05BX03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS ANTI-PARATHYROID AGENTS Other anti-parathyroid agents |
| FDA CS | M0007651 | Ergocalciferols |
| MeSH PA | D014815 | Vitamins |
| MeSH PA | D018977 | Micronutrients |
| MeSH PA | D050071 | Bone Density Conservation Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50188 | provitamin |
| CHEBI has role | CHEBI:50646 | bone density conservation agent |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:71212 | prohormone |
| FDA EPC | N0000175907 | Vitamin D2 Analog |
Related Drugs by ATC class:
H05BX Other anti-parathyroid agents 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis | indication | ||
| Hyperparathyroidism Secondary to Chronic Renal Failure | off-label use | ||
| Hyperphosphatemia | contraindication | 20165001 | DOID:0050459 |
| Hypervitaminosis D | contraindication | 27712000 | DOID:9971 |
| Hypoparathyroidism | contraindication | 36976004 | DOID:11199 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.7 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.5MCG | HECTOROL | SANOFI | N020862 | April 23, 2004 | DISCN | CAPSULE | ORAL | June 11, 2028 | ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
| 1MCG | HECTOROL | SANOFI | N020862 | July 13, 2009 | DISCN | CAPSULE | ORAL | June 11, 2028 | ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
| 2.5MCG | HECTOROL | SANOFI | N020862 | June 9, 1999 | DISCN | CAPSULE | ORAL | June 11, 2028 | ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Vitamin D3 receptor | Nuclear hormone receptor | AGONIST | UNKNOWN | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021201 | VUID |
| N0000179007 | NUI |
| D01009 | KEGG_DRUG |
| 4021201 | VANDF |
| C0043668 | UMLSCUI |
| CHEBI:4712 | CHEBI |
| V2H | PDB_CHEM_ID |
| CHEMBL1200810 | ChEMBL_ID |
| DB06410 | DRUGBANK_ID |
| 5281107 | PUBCHEM_CID |
| 2790 | IUPHAR_LIGAND_ID |
| C042533 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7878 | INN_ID |
| 3DIZ9LF5Y9 | UNII |
| 11516 | RXNORM |
| 211288 | MMSL |
| 30992 | MMSL |
| 8230 | MMSL |
| d04435 | MMSL |
| 007891 | NDDF |
| 116094003 | SNOMEDCT_US |
| 126234006 | SNOMEDCT_US |
| 3DIZ9LF5Y9 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-538 | CAPSULE | 0.50 ug | ORAL | ANDA | 22 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-539 | CAPSULE | 1 ug | ORAL | ANDA | 22 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-540 | CAPSULE | 2.50 ug | ORAL | ANDA | 22 sections |
| DOXERCALCIFEROL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-850 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 55150-357 | INJECTION, SOLUTION | 2 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 55150-357 | INJECTION, SOLUTION | 2 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 55150-358 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 55150-358 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 55150-359 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 55150-359 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-450 | CAPSULE | 0.50 ug | ORAL | ANDA | 17 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-451 | CAPSULE | 1 ug | ORAL | ANDA | 17 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-452 | CAPSULE | 2.50 ug | ORAL | ANDA | 17 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 62332-690 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 23 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 68083-300 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 68083-359 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-4642 | CAPSULE | 0.50 ug | ORAL | ANDA | 22 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-802 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 25 sections |